Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01728324 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 496
- Enrollment target
NCT01728324 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 496 participants.
The verdict
NCT01728324, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 496 participants
- Enrollment target
Study Summary
The aim of the study is to confirm efficacy and safety of treatment with 600 mg of BID BI 207127 in combination with 120 mg QD FDV and RBV for 16 or 24 weeks in target chronically infected HCV GT1b treatment naïve patients, including patients with compensated cirrhosis.
Interventions
- DRUG BI 207127-placebo: 8-week treatment
- DRUG Ribavirin: 24-week treatment
- DRUG BI 207127: 24-week treatment
- DRUG Faldaprevir: 24-week treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01728324
The ClinicalTrials.gov registry entry for NCT01728324 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 496 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BI 207127-placebo: 8-week treatment is the first listed.
NCT01728324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01728324 about?
NCT01728324 is a clinical study titled "Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2". The aim of the study is to confirm efficacy and safety of treatment with 600 mg of BID BI 207127 in combination with 120 mg QD FDV and RBV for 16 or 24 weeks in target chronically infected HCV GT1b treatment naïve patients, including patients with compensated cirrhosis.
What is the current status of trial NCT01728324?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 496 participants. The study started on 2012-11. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01728324?
The interventions under investigation include: BI 207127-placebo: 8-week treatment (DRUG), Ribavirin: 24-week treatment (DRUG), BI 207127: 24-week treatment (DRUG), Faldaprevir: 24-week treatment (DRUG).
Who is sponsoring clinical trial NCT01728324?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.